1,3,4-oxadiazole has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Devi, M; Kumar, A; Kumar, P; Lal, S; Sindhu, J; Singh, D; Singh, R; Toropov, AA; Toropova, AP | 1 |
| Akiyama, C; Chiba, K; Kagechika, K; Kobayashi, Y; Kubo, H; Nishi, M; Ono, M; Shibata, Y; Takano, H; Usui, H; Yamaguchi, M; Yoshikawa, K | 1 |
2 other study(ies) available for 1,3,4-oxadiazole and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Identifications of good and bad structural fragments of hydrazone/2,5-disubstituted-1,3,4-oxadiazole hybrids with correlation intensity index and consensus modelling using Monte Carlo based QSAR studies, their molecular docking and ADME analysis.
Topics: alpha-Amylases; Benzothiazoles; Consensus; Diabetes Mellitus, Type 2; Humans; Hydrazones; Models, Molecular; Molecular Docking Simulation; Oxadiazoles; Quantitative Structure-Activity Relationship | 2022 |
Synthesis and structure-activity relationships of novel zwitterionic compounds as peroxisome proliferator activated receptor α/γ dual agonists with improved physicochemical properties.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Design; Hypoglycemic Agents; Mice; Oxadiazoles; PPAR alpha; PPAR gamma; Structure-Activity Relationship | 2013 |